Pub Date : 2024-12-18DOI: 10.1016/j.xjidi.2024.100342
Justus Ohmes , Afsaneh Mehrpouyan , Julia Wimmer-Groß , Abdul Razzaque Ahmed , Kyle T. Amber , Swayanka Biswas , Angela Christiano , Shirin Emtenani , Stephanie Goletz , Jennifer Elisabeth Hundt , Laura Kirchhoff , Khalaf Kridin , Julie Lasselin , Matthias Laudes , Wing Yu Lee , Ralf J. Ludwig , Sripriya Murthy , Sadegh Mousavi , Tamas Nemeth , Mareike Neumann , Sarah Stenger
The International Congress on Autoimmune Pre-Disease was organized by the German Research Foundation–founded Research Training Group “Autoimmune Pre-Disease” and took place at the University of Lübeck, Germany, on September 16–17, 2024. The event featured various talks and posters from young researchers and international experts and emphasized early interventions and prevention in autoimmune diseases with a focus on systemic rheumatic diseases, pemphigus, and pemphigoid diseases.
{"title":"Meeting Report on “The International Congress on Autoimmune Pre-disease (2024)”","authors":"Justus Ohmes , Afsaneh Mehrpouyan , Julia Wimmer-Groß , Abdul Razzaque Ahmed , Kyle T. Amber , Swayanka Biswas , Angela Christiano , Shirin Emtenani , Stephanie Goletz , Jennifer Elisabeth Hundt , Laura Kirchhoff , Khalaf Kridin , Julie Lasselin , Matthias Laudes , Wing Yu Lee , Ralf J. Ludwig , Sripriya Murthy , Sadegh Mousavi , Tamas Nemeth , Mareike Neumann , Sarah Stenger","doi":"10.1016/j.xjidi.2024.100342","DOIUrl":"10.1016/j.xjidi.2024.100342","url":null,"abstract":"<div><div>The International Congress on Autoimmune Pre-Disease was organized by the German Research Foundation–founded Research Training Group “Autoimmune Pre-Disease” and took place at the University of Lübeck, Germany, on September 16–17, 2024. The event featured various talks and posters from young researchers and international experts and emphasized early interventions and prevention in autoimmune diseases with a focus on systemic rheumatic diseases, pemphigus, and pemphigoid diseases.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 3","pages":"Article 100342"},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143127846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-17DOI: 10.1016/j.xjidi.2024.100340
Ana Ribeiro , Catarina Pereira-Leite , Catarina Rosado , Edlira Aruci , Helen E. Colley , Inge Kortekaas Krohn , Ioana Baldea , Ivana Pantelić , Joachim W. Fluhr , Sandra I. Simões , Snežana Savić , Sofia A. Costa Lima
Skin acts as a dynamic interface with the environment. Pathological alterations in the skin barrier are associated with skin diseases. These conditions are characterized by specific impairments in epidermal barrier functions. Despite its protective nature, the skin can be a relevant route of drug administration, both for topical and transdermal therapy, allowing for improved drug delivery and reducing the incidence of adverse reactions. This manuscript reviews transcutaneous drug delivery as a strategy for treating localized and systemic conditions, highlighting the importance of skin models in the evaluation of drug efficacy and barrier function. It explores advances in in vitro, ex vivo, in vivo, and in silico models for studying cellular uptake, wound healing, oxidative stress, anti-inflammatory, and immune modulation activities. Disease-specific skin models are also discussed.
{"title":"Enhancing Transcutaneous Drug Delivery: Advanced Perspectives on Skin Models","authors":"Ana Ribeiro , Catarina Pereira-Leite , Catarina Rosado , Edlira Aruci , Helen E. Colley , Inge Kortekaas Krohn , Ioana Baldea , Ivana Pantelić , Joachim W. Fluhr , Sandra I. Simões , Snežana Savić , Sofia A. Costa Lima","doi":"10.1016/j.xjidi.2024.100340","DOIUrl":"10.1016/j.xjidi.2024.100340","url":null,"abstract":"<div><div>Skin acts as a dynamic interface with the environment. Pathological alterations in the skin barrier are associated with skin diseases. These conditions are characterized by specific impairments in epidermal barrier functions. Despite its protective nature, the skin can be a relevant route of drug administration, both for topical and transdermal therapy, allowing for improved drug delivery and reducing the incidence of adverse reactions. This manuscript reviews transcutaneous drug delivery as a strategy for treating localized and systemic conditions, highlighting the importance of skin models in the evaluation of drug efficacy and barrier function. It explores advances in in vitro, ex vivo, in vivo, and in silico models for studying cellular uptake, wound healing, oxidative stress, anti-inflammatory, and immune modulation activities. Disease-specific skin models are also discussed.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100340"},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143150345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-11DOI: 10.1016/j.xjidi.2024.100339
Meropi Karakioulaki , Patrick Dunn , Dedee F. Murrell , Aimee Payne , Enno Schmidt , Victoria Werth , Marc Yale , Jun Yamagami , Valeria Aoki , Luca Borradori , Frédéric Caux , Donna Culton , Maryam Daneshpazhooh , Dipankar De , Janet Fairley , Christoph Hammers , Michael Hertl , Maike Holtsche , Pascal Joly , Hiroshi Koga , Aikaterini Patsatsi
{"title":"Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece","authors":"Meropi Karakioulaki , Patrick Dunn , Dedee F. Murrell , Aimee Payne , Enno Schmidt , Victoria Werth , Marc Yale , Jun Yamagami , Valeria Aoki , Luca Borradori , Frédéric Caux , Donna Culton , Maryam Daneshpazhooh , Dipankar De , Janet Fairley , Christoph Hammers , Michael Hertl , Maike Holtsche , Pascal Joly , Hiroshi Koga , Aikaterini Patsatsi","doi":"10.1016/j.xjidi.2024.100339","DOIUrl":"10.1016/j.xjidi.2024.100339","url":null,"abstract":"","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100339"},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-11DOI: 10.1016/j.xjidi.2024.100338
Yin Li , Robert A. Swerlick
Background
Skin symptom burden, varying with patient populations, may not be readily observed by clinicians, resulting in incomplete appreciation of total skin disease burden.
Objective
The purpose of this study was to define patient itch burdens and associated health-related QOL affecting different patient demographics and to identify potential population health disparities.
Methods
This is a cross-sectional, secondary data analysis of data captured using an automated routine electronic previsit survey completed by patients who visited Emory Healthcare Dermatology clinic between March 2021 and October 2022 (6532 patient visits). Descriptive statistics and ordered logit regression analyses were used to examine the prevalence and intensity of itch and the impacts of itch on QOL.
Results
Overall itch burden increases as age increases; females and African Americans experienced more itch burden than males and other racial groups. Itch places significant symptom, emotional, and functional burdens on patients’ QOL, impacts that are independent of patients’ demographics.
Limitations
The data collected were from a single dermatology practice and may not be reflective of other practices or populations.
Conclusion
Dermatology previsit surveys are feasible in examining the significant pruritus burden, especially for older individuals, females, and African Americans with chronic skin conditions.
{"title":"Capture of Patient Itch Scores in Practice Reveals Disparate Itch Impact on the Basis of Age, Gender, and Race: A Cross-Sectional Survey Analysis","authors":"Yin Li , Robert A. Swerlick","doi":"10.1016/j.xjidi.2024.100338","DOIUrl":"10.1016/j.xjidi.2024.100338","url":null,"abstract":"<div><h3>Background</h3><div>Skin symptom burden, varying with patient populations, may not be readily observed by clinicians, resulting in incomplete appreciation of total skin disease burden.</div></div><div><h3>Objective</h3><div>The purpose of this study was to define patient itch burdens and associated health-related QOL affecting different patient demographics and to identify potential population health disparities.</div></div><div><h3>Methods</h3><div>This is a cross-sectional, secondary data analysis of data captured using an automated routine electronic previsit survey completed by patients who visited Emory Healthcare Dermatology clinic between March 2021 and October 2022 (6532 patient visits). Descriptive statistics and ordered logit regression analyses were used to examine the prevalence and intensity of itch and the impacts of itch on QOL.</div></div><div><h3>Results</h3><div>Overall itch burden increases as age increases; females and African Americans experienced more itch burden than males and other racial groups. Itch places significant symptom, emotional, and functional burdens on patients’ QOL, impacts that are independent of patients’ demographics.</div></div><div><h3>Limitations</h3><div>The data collected were from a single dermatology practice and may not be reflective of other practices or populations.</div></div><div><h3>Conclusion</h3><div>Dermatology previsit surveys are feasible in examining the significant pruritus burden, especially for older individuals, females, and African Americans with chronic skin conditions.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100338"},"PeriodicalIF":0.0,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-09DOI: 10.1016/j.xjidi.2024.100337
Rachita Pandya , Joshua Dan , Julianne Kleitsch , Darosa Lim , Barbara White , Victoria P. Werth
The Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM. In this study, data were analyzed from the phase 3 trial of lenabasum in DM. Cutaneous Dermatomyositis Disease Area and Severity Index-Activity scores and all components of the TIS were collected at baseline and weeks 16, 28, 40, and 52. From these assessments, a composite outcome was developed, named Dermatomyositis Outcomes for Muscle and Skin, which includes certain components of the TIS and the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity scores. The relative sensitivities of the TIS and Dermatomyositis Outcomes for Muscle and Skin to detect improvement in DM skin and muscle disease activity were analyzed. A total of 174 patients with DM were included, 82% were female, and 75% were White. Mean (SD) age was 51.9 (12.20) years. Treatment effect using the TIS ranged between 17.6 and 21.7 points for muscle and skin responders versus nonresponders across time points. The Dermatomyositis Outcomes for Muscle and Skin score displayed a statistically significantly greater treatment effect of 25.9–40.0 points for responders than for nonresponders, depending on the response assessed and the time point. Dermatomyositis Outcomes for Muscle and Skin is a more sensitive composite measure that reflects improvement from baseline in both skin and muscle disease activity, suggesting usefulness for use in future DM clinical trials.
{"title":"Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials","authors":"Rachita Pandya , Joshua Dan , Julianne Kleitsch , Darosa Lim , Barbara White , Victoria P. Werth","doi":"10.1016/j.xjidi.2024.100337","DOIUrl":"10.1016/j.xjidi.2024.100337","url":null,"abstract":"<div><div>The Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM. In this study, data were analyzed from the phase 3 trial of lenabasum in DM. Cutaneous Dermatomyositis Disease Area and Severity Index-Activity scores and all components of the TIS were collected at baseline and weeks 16, 28, 40, and 52. From these assessments, a composite outcome was developed, named Dermatomyositis Outcomes for Muscle and Skin, which includes certain components of the TIS and the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity scores. The relative sensitivities of the TIS and Dermatomyositis Outcomes for Muscle and Skin to detect improvement in DM skin and muscle disease activity were analyzed. A total of 174 patients with DM were included, 82% were female, and 75% were White. Mean (SD) age was 51.9 (12.20) years. Treatment effect using the TIS ranged between 17.6 and 21.7 points for muscle and skin responders versus nonresponders across time points. The Dermatomyositis Outcomes for Muscle and Skin score displayed a statistically significantly greater treatment effect of 25.9–40.0 points for responders than for nonresponders, depending on the response assessed and the time point. Dermatomyositis Outcomes for Muscle and Skin is a more sensitive composite measure that reflects improvement from baseline in both skin and muscle disease activity, suggesting usefulness for use in future DM clinical trials.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100337"},"PeriodicalIF":0.0,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-04DOI: 10.1016/j.xjidi.2024.100336
Marita Jenssen , Nikhil Arora , Mari Løset , Bjørn Olav Åsvold , Laurent Thomas , Ole-Jørgen Bekkevold Vassmyr , Xiao-Mei Mai , Yi-Qian Sun , Anne-Sofie Furberg , Rolf Jorde , Tom Wilsgaard , Kjersti Danielsen , Ben Michael Brumpton
Mendelian randomization (MR) studies show that higher body mass index (BMI) and lower 25-hydroxyvitamin D (25[OH]D) increase psoriasis risk. The combined effect of these factors has not been explored using factorial MR. Using cross-sectional data from UK Biobank (n = 398,404) and The Trøndelag Health Study (n = 86,648), we calculated polygenic risk scores for BMI and 25(OH)D to estimate ORs for psoriasis using 2 × 2 and continuous factorial MR. We quantified additive interaction by estimating relative excess risk due to interaction. We also performed traditional observational analyses in UK Biobank. There were 12,207 (3.1%) participants with psoriasis in UK Biobank and 7794 (9.0%) in The Trøndelag Health Study. In 2 × 2 factorial MR, we found no evidence of relative excess risk for psoriasis due to interaction between genetically predicted higher BMI and lower 25(OH)D, neither in UK Biobank (relative excess risk due to interaction = −0.01, 95% confidence interval = −0.08 to 0.07) nor in The Trøndelag Health Study (relative excess risk due to interaction = −0.04, 95% confidence interval = −0.14 to 0.06). The same was observed in the continuous factorial MR and observational analyses. In conclusion, this study did not find evidence of interaction between BMI and 25(OH)D on the risk of psoriasis. Given minor differences in measured BMI and 25(OH)D between the factorial groups, small effects may have been undetected.
{"title":"Exploring Interaction between Genetically Predicted Body Mass Index and Serum 25-Hydroxyvitamin D Levels on the Odds for Psoriasis in UK Biobank and the HUNT Study: A Factorial Mendelian Randomization Study","authors":"Marita Jenssen , Nikhil Arora , Mari Løset , Bjørn Olav Åsvold , Laurent Thomas , Ole-Jørgen Bekkevold Vassmyr , Xiao-Mei Mai , Yi-Qian Sun , Anne-Sofie Furberg , Rolf Jorde , Tom Wilsgaard , Kjersti Danielsen , Ben Michael Brumpton","doi":"10.1016/j.xjidi.2024.100336","DOIUrl":"10.1016/j.xjidi.2024.100336","url":null,"abstract":"<div><div>Mendelian randomization (MR) studies show that higher body mass index (BMI) and lower 25-hydroxyvitamin D (25[OH]D) increase psoriasis risk. The combined effect of these factors has not been explored using factorial MR. Using cross-sectional data from UK Biobank (n = 398,404) and The Trøndelag Health Study (n = 86,648), we calculated polygenic risk scores for BMI and 25(OH)D to estimate ORs for psoriasis using 2 × 2 and continuous factorial MR. We quantified additive interaction by estimating relative excess risk due to interaction. We also performed traditional observational analyses in UK Biobank. There were 12,207 (3.1%) participants with psoriasis in UK Biobank and 7794 (9.0%) in The Trøndelag Health Study. In 2 × 2 factorial MR, we found no evidence of relative excess risk for psoriasis due to interaction between genetically predicted higher BMI and lower 25(OH)D, neither in UK Biobank (relative excess risk due to interaction = −0.01, 95% confidence interval = −0.08 to 0.07) nor in The Trøndelag Health Study (relative excess risk due to interaction = −0.04, 95% confidence interval = −0.14 to 0.06). The same was observed in the continuous factorial MR and observational analyses. In conclusion, this study did not find evidence of interaction between BMI and 25(OH)D on the risk of psoriasis. Given minor differences in measured BMI and 25(OH)D between the factorial groups, small effects may have been undetected.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100336"},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143150993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-03DOI: 10.1016/j.xjidi.2024.100335
Joanna Dong , Naiem T. Issa , Michael Kaiser , Simonetta I. Gaumond , Michael Solis , Joel Gil , Robert S. Kirsner , Stephen C. Davis , Joaquin J. Jimenez
Owing to the increasingly high volume of cutaneous and percutaneous procedures performed annually, the demand for local anesthesia has steadily risen. The gold-standard formulations for local anesthesia contain epinephrine at a concentration of 1:100,000 added to lidocaine to aid in hemostasis. Epinephrine, an α-agonist, also exhibits off-target β-adrenergic effects that carry risk of adverse events with these injections. Furthermore, the ongoing global shortage of epinephrine highlights the need for a safer and viable alternative. Midodrine, a targeted a1-adrenergic receptor agonist, is utilized as a vasopressor to induce arterial and venous vasoconstriction. We developed a formulation of 2% lidocaine combined with 1:2,000,000 epinephrine and 50 μM midodrine (midodrine/lidocaine/epinephrine formulation), hypothesizing that this combination would exhibit synergism on hemostasis. In a porcine model of blood loss after punch biopsies, our formulation was compared with 2% lidocaine; 2% lidocaine with 1:100,000 epinephrine; 2% lidocaine with 1:2,000,000 epinephrine; and 2% lidocaine with 50 μM midodrine. Our results indicate that 2% lidocaine with 1:100,000 epinephrine and our midodrine/lidocaine/epinephrine formulation were statistically comparable, with both significantly reducing bleeding when compared with the 2% lidocaine (P < .05). The 2% lidocaine with midodrine alone also showed additional promise as an effective hemostatic formulation. Thus, combination of low-concentration epinephrine and midodrine with lidocaine may exhibit synergistic hemostatic effect in cutaneous surgical settings while reducing potential off-target effects of either vasoconstrictor alone at higher concentrations as adjunct monotherapies.
{"title":"Use of Midodrine for Intraoperative Hemostasis in Cutaneous and Percutaneous Surgery","authors":"Joanna Dong , Naiem T. Issa , Michael Kaiser , Simonetta I. Gaumond , Michael Solis , Joel Gil , Robert S. Kirsner , Stephen C. Davis , Joaquin J. Jimenez","doi":"10.1016/j.xjidi.2024.100335","DOIUrl":"10.1016/j.xjidi.2024.100335","url":null,"abstract":"<div><div>Owing to the increasingly high volume of cutaneous and percutaneous procedures performed annually, the demand for local anesthesia has steadily risen. The gold-standard formulations for local anesthesia contain epinephrine at a concentration of 1:100,000 added to lidocaine to aid in hemostasis. Epinephrine, an α-agonist, also exhibits off-target β-adrenergic effects that carry risk of adverse events with these injections. Furthermore, the ongoing global shortage of epinephrine highlights the need for a safer and viable alternative. Midodrine, a targeted a<sub>1</sub>-adrenergic receptor agonist, is utilized as a vasopressor to induce arterial and venous vasoconstriction. We developed a formulation of 2% lidocaine combined with 1:2,000,000 epinephrine and 50 μM midodrine (midodrine/lidocaine/epinephrine formulation), hypothesizing that this combination would exhibit synergism on hemostasis. In a porcine model of blood loss after punch biopsies, our formulation was compared with 2% lidocaine; 2% lidocaine with 1:100,000 epinephrine; 2% lidocaine with 1:2,000,000 epinephrine; and 2% lidocaine with 50 μM midodrine. Our results indicate that 2% lidocaine with 1:100,000 epinephrine and our midodrine/lidocaine/epinephrine formulation were statistically comparable, with both significantly reducing bleeding when compared with the 2% lidocaine (<em>P</em> < .05). The 2% lidocaine with midodrine alone also showed additional promise as an effective hemostatic formulation. Thus, combination of low-concentration epinephrine and midodrine with lidocaine may exhibit synergistic hemostatic effect in cutaneous surgical settings while reducing potential off-target effects of either vasoconstrictor alone at higher concentrations as adjunct monotherapies.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100335"},"PeriodicalIF":0.0,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143150992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-29DOI: 10.1016/j.xjidi.2024.100333
Sneha Shrotri , Andrea Daamen , Kathryn Kingsmore , Prathyusha Bachali , Amrie Grammer , Peter Lipsky
Abnormalities in gene expression profiles characterize patients with inflammatory skin diseases, including psoriasis, and changes may reflect the action of specific therapeutic agents. To examine this, gene expression analysis of psoriatic skin was assessed by Gene Set Variation Analysis using informative gene modules, and longitudinal data were analyzed to assess the impact of various treatments. Ridge penalized logistic regression was employed to derive a transcriptomic score. Psoriatic lesional skin exhibited perturbations in gene expression profiles at baseline, with enrichment of signatures for neutrophils, keratinocytes, IFN, IL-12 complex, IL-1 cytokines, TNF, and T helper 17. Treatment with a variety of agents reduced lesional gene expression abnormalities to those in nonlesional skin. Specific gene expression abnormalities at baseline identified clinical responders to each treatment. Changes in gene expression over time were less pronounced in nonlesional skin and lesional skin in clinical nonresponders. The combined transcriptomic scores showed significant positive correlations with PASI scores in clinical responders over time. Overall, gene expression abnormalities characterize the severity of psoriatic skin lesions, can be used to predict responsiveness to individual treatments, and revert toward those of nonlesional skin with effective therapy. Therefore, gene expression analysis can be useful to support management of patients with psoriasis.
{"title":"Transcriptomic Analysis Identifies Disease Severity and Therapeutic Response in Psoriasis","authors":"Sneha Shrotri , Andrea Daamen , Kathryn Kingsmore , Prathyusha Bachali , Amrie Grammer , Peter Lipsky","doi":"10.1016/j.xjidi.2024.100333","DOIUrl":"10.1016/j.xjidi.2024.100333","url":null,"abstract":"<div><div>Abnormalities in gene expression profiles characterize patients with inflammatory skin diseases, including psoriasis, and changes may reflect the action of specific therapeutic agents. To examine this, gene expression analysis of psoriatic skin was assessed by Gene Set Variation Analysis using informative gene modules, and longitudinal data were analyzed to assess the impact of various treatments. Ridge penalized logistic regression was employed to derive a transcriptomic score. Psoriatic lesional skin exhibited perturbations in gene expression profiles at baseline, with enrichment of signatures for neutrophils, keratinocytes, IFN, IL-12 complex, IL-1 cytokines, TNF, and T helper 17. Treatment with a variety of agents reduced lesional gene expression abnormalities to those in nonlesional skin. Specific gene expression abnormalities at baseline identified clinical responders to each treatment. Changes in gene expression over time were less pronounced in nonlesional skin and lesional skin in clinical nonresponders. The combined transcriptomic scores showed significant positive correlations with PASI scores in clinical responders over time. Overall, gene expression abnormalities characterize the severity of psoriatic skin lesions, can be used to predict responsiveness to individual treatments, and revert toward those of nonlesional skin with effective therapy. Therefore, gene expression analysis can be useful to support management of patients with psoriasis.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100333"},"PeriodicalIF":0.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-29DOI: 10.1016/j.xjidi.2024.100334
Ron Feldman , Emily F. Cole
With a growing awareness of climate change, air pollution has emerged as an important contributor to the development and exacerbation of inflammatory skin conditions. However, the effect of air pollution on immunobullous disease activity is unknown. In this study, we performed a retrospective cohort study of 115 patients with bullous pemphigoid and 152 patients with pemphigus from a university-based specialty clinic in the Southeastern United States. We compared standardized disease activity measures with inhalable particulate matter (particulate matter ≤2.5, particulate matter ≤10), ozone, atmospheric pollutants (sulphur dioxide, carbon monoxide, nitrogen dioxide), and air quality index. Results demonstrated small but statistically significant associations between Bullous Pemphigoid Disease Area Index total activity score and several variables (particulate matter ≤2.5, sulphur dioxide, and air quality index). In addition, there were small but significant negative correlations between ozone and bullous pemphigoid disease area index pruritus score as well as carbon monoxide and pemphigus disease area index score. This study suggests that air pollution may impact disease activity in bullous pemphigoid to a greater extent than pemphigus. Future studies should be aimed at identifying potential mechanisms for this association.
{"title":"The Impact of Air Pollution on Disease Activity in Bullous Pemphigoid and Pemphigus","authors":"Ron Feldman , Emily F. Cole","doi":"10.1016/j.xjidi.2024.100334","DOIUrl":"10.1016/j.xjidi.2024.100334","url":null,"abstract":"<div><div>With a growing awareness of climate change, air pollution has emerged as an important contributor to the development and exacerbation of inflammatory skin conditions. However, the effect of air pollution on immunobullous disease activity is unknown. In this study, we performed a retrospective cohort study of 115 patients with bullous pemphigoid and 152 patients with pemphigus from a university-based specialty clinic in the Southeastern United States. We compared standardized disease activity measures with inhalable particulate matter (particulate matter ≤2.5, particulate matter ≤10), ozone, atmospheric pollutants (sulphur dioxide, carbon monoxide, nitrogen dioxide), and air quality index. Results demonstrated small but statistically significant associations between Bullous Pemphigoid Disease Area Index total activity score and several variables (particulate matter ≤2.5, sulphur dioxide, and air quality index). In addition, there were small but significant negative correlations between ozone and bullous pemphigoid disease area index pruritus score as well as carbon monoxide and pemphigus disease area index score. This study suggests that air pollution may impact disease activity in bullous pemphigoid to a greater extent than pemphigus. Future studies should be aimed at identifying potential mechanisms for this association.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 3","pages":"Article 100334"},"PeriodicalIF":0.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-28DOI: 10.1016/j.xjidi.2024.100332
Andrew W. Miller , Alexa R. Anderson , Alejandra Suarez-Arnedo , Tatiana Segura
With the goal of studying skin wound healing and testing new drug treatments to enhance wound healing in rodent models, there is a clear need for improved splinting techniques to increase surgical efficiency and support routine wound monitoring. Splinted wound healing models humanize wound healing in rodents to prevent contraction and instead heal through granulation tissue deposition, increasing the relevance to human wound healing. Current technologies require suturing and heavy wrapping, leading to splint failure and cumbersome monitoring of the wound. In this study, we developed a splint with resealable cap system that provides ease of access for wound inspection, therapeutic treatment delivery, and routine wound imaging without the need to unwrap and wrap the animal. Meanwhile, to overcome the challenges associated with suturing, we also developed adherent splints that can be applied to both hairless or haired mice with minimal wrapping. Both technologies are expected to improve and encourage the adoption of splinted wound healing models.
{"title":"Wound Healing Splinting Devices for Faster Access and Use","authors":"Andrew W. Miller , Alexa R. Anderson , Alejandra Suarez-Arnedo , Tatiana Segura","doi":"10.1016/j.xjidi.2024.100332","DOIUrl":"10.1016/j.xjidi.2024.100332","url":null,"abstract":"<div><div>With the goal of studying skin wound healing and testing new drug treatments to enhance wound healing in rodent models, there is a clear need for improved splinting techniques to increase surgical efficiency and support routine wound monitoring. Splinted wound healing models humanize wound healing in rodents to prevent contraction and instead heal through granulation tissue deposition, increasing the relevance to human wound healing. Current technologies require suturing and heavy wrapping, leading to splint failure and cumbersome monitoring of the wound. In this study, we developed a splint with resealable cap system that provides ease of access for wound inspection, therapeutic treatment delivery, and routine wound imaging without the need to unwrap and wrap the animal. Meanwhile, to overcome the challenges associated with suturing, we also developed adherent splints that can be applied to both hairless or haired mice with minimal wrapping. Both technologies are expected to improve and encourage the adoption of splinted wound healing models.</div></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"5 2","pages":"Article 100332"},"PeriodicalIF":0.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号